238. Vitamin D-resistant rickets
[
1 clinical trial,
1 drug（DrugBank:
0 drug),
0 target gene / 0 target pathway ]
Searched query = "Vitamin D resistant rickets", "Vitamin D resistant osteomalacia", "VDRR", "FGF23 related hypophosphatemic disease", "FGF23 related hypophosphatemia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-101332 | 01/9/2010 | 23 April 2019 | Therapeutic use of Z-521 | Therapeutic use of oral sodium phosphate (Z-521) in primary hypophosphatemic rickets (familial rickets, X-linked hypophosphatemia, vitamin D-resistant rickets) | primary hypophosphatemic rickets | Intervention name : Z-521 Dosage And administration of the intervention : 300-3000mg inorganic phosphorus is orally administered in 3 or 4 times per day | Zeria Pharmaceutical Co., Ltd. | 1 | 14 | BOTH | 10 | Phase 3 |